Department of Chemistry (R.A.T., R.D., M.A.) and Faculty of Sustainable Design Engineering (M.A.), University of Prince Edward Island, Charlottetown, Canada.
Department of Chemistry (R.A.T., R.D., M.A.) and Faculty of Sustainable Design Engineering (M.A.), University of Prince Edward Island, Charlottetown, Canada
J Pharmacol Exp Ther. 2024 Jun 21;390(1):53-64. doi: 10.1124/jpet.123.002016.
Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer and is associated with high probability of metastasis and poor prognosis. Chemotherapeutics and surgery remain the most common options for TNBC patients; however, chemotherapeutic resistance and relapse of tumors limit the progression free survival and patient life span. This review provides an overview of recent chemotherapeutics that are in clinical trial, and the combination of drugs that are being investigated to overcome the drug resistance and to improve patient survival in different molecular subtypes of TNBCs. Nanotherapeutics have emerged as a promising platform for TNBC treatment and aim to improve the selectivity and solubility of drugs, reduce systemic side effects, and overcome multi-drug resistance. The study explores the role of nanoparticles for TNBC treatment and summarizes the types of nanoparticles that are in clinical trials. Poly(L-lactide-co-glycolide) (PLGA) is the most studied polymeric carrier for drug delivery and for TNBC treatment in research and in clinics. This review is about providing recent advancements in PLGA nanotherapeutic formulations and their application to help treat TNBC. Some background on current chemotherapies and pathway inhibitors is provided so that the readers are aware of what is currently considered for TNBC. Some of the pathway inhibitors may also be of importance for nanotherapeutics development. SIGNIFICANCE STATEMENT: This minireview summarizes the progress on chemotherapeutics and nanoparticle delivery for treatment of TNBC and specifically highlights the lead compounds that are in clinical trials.
三阴性乳腺癌（TNBC）是最具侵袭性的乳腺癌类型，其转移概率高，预后不良。化疗和手术仍然是 TNBC 患者的最常见选择；然而，化疗耐药和肿瘤复发限制了无进展生存期和患者寿命。本综述概述了正在临床试验中的最新化疗药物，并组合了正在研究的药物，以克服耐药性并改善不同分子亚型 TNBC 患者的生存。纳米疗法已成为治疗 TNBC 的有前途的平台，旨在提高药物的选择性和溶解性，减少全身副作用，并克服多药耐药性。该研究探讨了纳米颗粒在 TNBC 治疗中的作用，并总结了正在临床试验中的纳米颗粒类型。聚（L-丙交酯-co-乙交酯）（PLGA）是研究和临床中用于药物递送和 TNBC 治疗的最常用聚合物载体。本综述旨在提供 PLGA 纳米治疗制剂的最新进展及其在帮助治疗 TNBC 中的应用。提供了一些关于当前化疗药物和通路抑制剂的背景知识，以便读者了解目前对 TNBC 的治疗方法。一些通路抑制剂也可能对纳米疗法的发展很重要。意义陈述：本迷你综述总结了针对 TNBC 的化疗和纳米颗粒递送治疗的进展，并特别强调了正在临床试验中的主导化合物。
